Close Menu

NEW YORK – Bioprinting technology developer Cellink has signed an agreement to acquire all shares of German precision dispensing firm Scienion for €80 million ($94.8 million).

Under the terms of the deal, Boston-based Cellink will acquire Scienion for €40 million in cash and €40 million in shares through 2,814,032 newly issued shares at a price of SEK 146.6 per share. The transaction will give Scienion's shareholders about a 5 percent voting stake and roughly 7 percent of the firm's share capital. Following the acquisition, Scienion will retain its current management. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.